Treatment of increased menstrual blood loss in iud users

Toppozada, M.

doi:10.1016/0010-7824(87)90066-7

Cited by 8 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Indomethacin 25 mg 4 times daily for 3 days with menses was also associated with a significant reduction in blood loss of 38% (P<.01). 11 Another trial of indomethacin used 25 mg twice daily for 7 days initiated at the start of menses in women who reported heavy or prolonged bleeding and noted a significant reduction in the number of bleeding/spotting days (10 fewer days per 90-day cycle) as well as length of bleeding episode (approximately 3 days less). 12 Mefenamic acid 100 mg 3 times daily for 3 days, given several days before expected menstruation or with the start of menses, was also associated with a significant reduction in blood loss (P<.01).…”

Section: Nonsteroidal Antiinflammatory Drugsmentioning

confidence: 98%

Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception

Friedländer

Kaneshiro

2015

Obstetrics and Gynecology Clinics of North America

View full text Add to dashboard Cite

Section: Nonsteroidal Antiinflammatory Drugsmentioning

confidence: 98%

Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception

Friedländer

Kaneshiro

2015

Obstetrics and Gynecology Clinics of North America

View full text Add to dashboard Cite

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use

Christelle

Norhayati

Jaafar

2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Prostaglandins and cellular reaction in uterine flushings. II. Effect of PG synthesis inhibition in IUD users

et al. 1987

View full text Add to dashboard Cite

The effect of oral administration of indomethacin (100 mg/day), a potent inhibitor of prostaglandin (PG) biosynthesis, on the PG levels and cellular profile in the uterine flushings in response to the use of an IUD (Lippes Loop size C) was studied in sixty women. Indomethacin reduced the cell counts in both follicular and luteal phases of menstrual cycles before and after IUD insertion. The anti-inflammatory drug decreased PGE2 and PGF2 alpha levels in both phases of the cycle before IUD insertion. After insertion, it inhibited only the formation of PGF2 alpha and its 13,14-dihydro-15-keto metabolite in the luteal phase but not in the follicular phase. In long-term users, however, the drugs reduced the levels of all PGs studied in the luteal phase and only PGF2 alpha and its metabolite in the follicular phase. The implications of these findings in the mechanisms of contraceptive action of IUDs and their side effects are discussed.

show abstract

Treatment of increased menstrual blood loss in iud users

Cited by 8 publications

References 16 publications

Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception

Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use

Prostaglandins and cellular reaction in uterine flushings. II. Effect of PG synthesis inhibition in IUD users

Contact Info

Product

Resources

About